Relapse/Refractory Myelofibrosis – PSI – 045-2020

People with Relapse/Refractory Myelofibrosis are asked to participate in a research study being conducted by Monter Cancer Center.

You may be eligible to participate in this study if you:

• Are a male or female at least 18 years of age
• Have confirmed diagnosis of primary MF, post–PV MF, or post–ET MF
• Have adequate hematological, hepatic, and renal organ function

You may NOT participate in this study if you:

• Have prior MDM2 inhibitor therapy or TP53-directed therapy
• Have Prior treatment with any BTK, BMX, BCR-ABL, PI3k, mTOR, bromodomain and extraterminal domain (BET), histone deacetylase (HDAC), or spleen tyrosine kinase (Syk) inhibitor
• Major surgery within 28 days
• Have clinically significant bacterial, fungal, parasitic, or viral infection that requires therapy
• Have history of major organ transplant
• Have known immunodeficiency virus (HIV) infection, hepatitis B or C
• Are pregnant or breastfeeding

Contact Information
Arpana Manuel, Study Coordinator
450 Lakeville Road
Lake Success, NY 11042
Phone: (516) 734-8921